Seres Therapeutics (MCRB) announced that new post hoc data from its SER-155 Phase 1b trial will be featured in an oral presentation at IDWeek 2025, taking place October 19-22 in Atlanta, Georgia. The presentation will include new data describing differences between the SER-155 and placebo groups in the bacterial and fungal organisms causing BSIs, including BSI event clinical outcomes, antibacterial prophylaxis use, and patterns of antimicrobial resistance among the bacterial BSI organisms.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCRB: